ARK Genomic Revolution ETF (BATS:ARKG) Shares Sold by Creative Planning

Creative Planning trimmed its stake in shares of ARK Genomic Revolution ETF (BATS:ARKG) by 10.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,737 shares of the company’s stock after selling 1,117 shares during the quarter. Creative Planning’s holdings in ARK Genomic Revolution ETF were worth $249,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Janney Montgomery Scott LLC grew its position in shares of ARK Genomic Revolution ETF by 14.2% during the first quarter. Janney Montgomery Scott LLC now owns 8,425 shares of the company’s stock worth $242,000 after buying an additional 1,045 shares in the last quarter. Clearwater Capital Advisors LLC lifted its stake in ARK Genomic Revolution ETF by 3.8% in the first quarter. Clearwater Capital Advisors LLC now owns 173,759 shares of the company’s stock worth $4,997,000 after acquiring an additional 6,385 shares during the last quarter. Longitude Cayman Ltd. grew its holdings in ARK Genomic Revolution ETF by 8.8% during the 1st quarter. Longitude Cayman Ltd. now owns 87,000 shares of the company’s stock worth $2,502,000 after acquiring an additional 7,000 shares in the last quarter. Cetera Investment Advisers increased its position in shares of ARK Genomic Revolution ETF by 290.7% in the 1st quarter. Cetera Investment Advisers now owns 140,897 shares of the company’s stock valued at $4,052,000 after purchasing an additional 104,831 shares during the last quarter. Finally, Cetera Advisors LLC raised its holdings in shares of ARK Genomic Revolution ETF by 2.2% in the 1st quarter. Cetera Advisors LLC now owns 65,670 shares of the company’s stock valued at $1,889,000 after purchasing an additional 1,407 shares in the last quarter.

ARK Genomic Revolution ETF Price Performance

ARK Genomic Revolution ETF stock opened at $25.90 on Monday. The stock’s 50-day moving average price is $24.88 and its two-hundred day moving average price is $25.12.

ARK Genomic Revolution ETF Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.